Gypenoside LICAS# 94987-10-7 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
| Cas No. | 94987-10-7 | SDF | Download SDF |
| PubChem ID | N/A | Appearance | Powder |
| Formula | C42H72O14 | M.Wt | 801.0 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Gypenoside LI Dilution Calculator
Gypenoside LI Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.2484 mL | 6.2422 mL | 12.4844 mL | 24.9688 mL | 31.211 mL |
| 5 mM | 0.2497 mL | 1.2484 mL | 2.4969 mL | 4.9938 mL | 6.2422 mL |
| 10 mM | 0.1248 mL | 0.6242 mL | 1.2484 mL | 2.4969 mL | 3.1211 mL |
| 50 mM | 0.025 mL | 0.1248 mL | 0.2497 mL | 0.4994 mL | 0.6242 mL |
| 100 mM | 0.0125 mL | 0.0624 mL | 0.1248 mL | 0.2497 mL | 0.3121 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Rheumone B
Catalog No.:BCN8996
CAS No.:2095596-67-9
- 2-(2-Phenylethyl)chromone
Catalog No.:BCN8995
CAS No.:61828-53-3
- Siaresinolic acid 28-O-beta-D-glucopyranosyl ester
Catalog No.:BCN8994
CAS No.:155653-86-4
- Isorhamnetin 3-O-beta-D-glucose-7-O-beta-D-gentiobioside
Catalog No.:BCN8993
CAS No.:60778-00-9
- Regaloside L
Catalog No.:BCN8992
CAS No.:
- Sibiricose A1
Catalog No.:BCN8991
CAS No.:139726-40-2
- Eupalinolide O
Catalog No.:BCN8990
CAS No.:2170228-67-6
- Damulin B
Catalog No.:BCN8989
CAS No.:1202868-75-4
- Achyranthoside C
Catalog No.:BCN8988
CAS No.:168009-90-3
- Hispidulin 4'-O-beta-D-glucopyranoside
Catalog No.:BCN8987
CAS No.:244285-12-9
- Pongamol
Catalog No.:BCN8986
CAS No.:484-33-3
- 11-(Methylsulfinyl)undecylglucosinolate
Catalog No.:BCN8980
CAS No.:
- Hemiphloin
Catalog No.:BCN8998
CAS No.:71963-94-5
- Quercetagetinidin chloride
Catalog No.:BCN8999
CAS No.:42529-06-6
- Kaempferidinidin chloride
Catalog No.:BCN9000
CAS No.:13544-52-0
- Fisetinidin chloride
Catalog No.:BCN9001
CAS No.:2948-76-7
- Apigeninidin chloride
Catalog No.:BCN9002
CAS No.:1151-98-0
- Cyanidin-3-O-sambubioside-5-O-glucoside chloride
Catalog No.:BCN9003
CAS No.:53925-33-0
- Peonidin-3-O-rutinoside chloride
Catalog No.:BCN9005
CAS No.:27539-32-8
- Delphinidin-3-O-rhamnoside chloride
Catalog No.:BCN9006
CAS No.:29907-19-5
- Achyranthoside D
Catalog No.:BCN9008
CAS No.:168009-91-4
- Damulin A
Catalog No.:BCN9009
CAS No.:1202868-74-3
- Regaloside D
Catalog No.:BCN9010
CAS No.:120601-66-3
- 4'-hydroxy-6,7,8,3'-tetramethoxyflavonol
Catalog No.:BCN9011
CAS No.:1879030-01-9
Monomer gypenoside LI from Gynostemma pentaphyllum inhibits cell proliferation and upregulates expression of miR-128-3p in melanoma cells.[Pubmed:32022984]
J Biochem Mol Toxicol. 2020 May;34(5):e22460.
Gypenosides have anticancer activity against many cancers. Gypenoside LI is a gypenoside monomer from Gynostemma pentaphyllum, its pharmacological functions in melanoma have not been reported. In this study, we found that Gypenoside LI had a potent cytotoxic effect on melanoma cells. Gypenoside LI can induce intrinsic apoptosis along with S phase arrest. Furthermore, Gypenoside LI inhibited the colony formation ability of melanoma through inhibition of the Wnt/beta-catenin signaling pathway. Interestingly, we also found that Gypenoside LI can induce the upregulation of the tumor suppressor miR-128-3p during melanoma apoptosis. In contrast, Gypenoside LI induced apoptosis, cell cycle arrest, and inhibition of the Wnt/beta-catenin signaling pathway, which were abolished by overexpression of the miR-128-3p inhibitor in A375 cells. Taken together, these results showed that Gypenoside LI could inhibit human melanoma cells through inducing apoptosis, arresting cell cycle at the S phase and suppressing the Wnt/beta-catenin signaling pathway in a miR-128-3p dependent manner.
Gynostemma Pentaphyllum Extract Ameliorates High-Fat Diet-Induced Obesity in C57BL/6N Mice by Upregulating SIRT1.[Pubmed:31618980]
Nutrients. 2019 Oct 15;11(10). pii: nu11102475.
Gynostemma pentaphyllum is widely used in Asia as a herbal medicine to treat type 2 diabetes, dyslipidemia, and inflammation. Here, we investigated the anti-obesity effect and underlying mechanism of G. pentaphyllum extract (GPE) enriched in gypenoside L, Gypenoside LI, and ginsenoside Rg3 and obtained using a novel extraction method. Five-week-old male C57BL/6N mice were fed a control diet (CD), high-fat diet (HFD), HFD + 100 mg/kg body weight (BW)/day GPE (GPE 100), HFD + 300 mg/kg BW/day GPE (GPE 300), or HFD + 30 mg/kg BW/day Orlistat (Orlistat 30) for 8 weeks. The HFD-fed mice showed significant increases in body weight, fat mass, white adipose tissue, and adipocyte hypertrophy compared to the CD group; but GPE inhibited those increases. GPE reduced serum levels of triglyceride, total cholesterol, and LDL-cholesterol, without affecting HDL-cholesterol. GPE significantly increased AMPK activation and suppressed adipogenesis by decreasing the mRNA expression of CCAAT/enhancer binding protein-alpha (C/EBPalpha), peroxisome proliferator-activated receptor-gamma (PPARgamma), sterol regulatory element-binding protein-1c (SREBP1c), PPARgamma coactivator-1alpha, fatty acid synthase (FAS), adipocyte protein 2 (AP2), and sirtuin 1 (SIRT1) and by increasing that of carnitine palmitoyltransferase (CPT1) and hormone- sensitive lipase (HSL). This study demonstrated the ameliorative effect of GPE on obesity and elucidated the underlying molecular mechanism.
